Immunology and Microbiology
Actin
17%
Agonist
45%
Antigen Presentation
22%
Antigen-Presenting Cell
17%
B Cell
53%
Bacilli
17%
Cancer Antibody
17%
Carcinoembryonic Antigen
17%
CCR2
17%
CD19
61%
CD20
22%
Cell Activation
17%
Cell Activity
17%
Cell Death
20%
Chimeric Antigen Receptor
25%
Chimeric Antigen Receptor T-Cell
62%
Cytokine
17%
Dendritic Cell
34%
Eotaxin 2
17%
Escherichia Coli Vaccine
17%
Immune Checkpoint Blockade
11%
Immune Response
51%
Immunity
21%
Immunosuppressive Drug
29%
Immunotherapy
68%
Interleukin 12
17%
Intravenous Immunoglobulin
51%
Low Drug Dose
14%
Lymphocyte Count
34%
Lymphoma Cell
17%
Lysosome
17%
MHC Class I
17%
Monoclonal Antibody
11%
Mouse
40%
Mouse Model
19%
Mycobacterium bovis
17%
Natural Killer Cell
17%
Obinutuzumab
34%
Oropharynx
17%
Overall Survival
25%
Programmed Death-Ligand 1
39%
Rituximab
34%
Secretion (Process)
9%
Syngenic
18%
T Cell
100%
T-Helper Cell
22%
TLR7
22%
Toll-Like Receptor
34%
Tumor Cell
16%
Vaccine Efficacy
12%
Medicine and Dentistry
Autologous Tumor Cell
6%
B-Cell Lymphoma
20%
Cancer Cell
17%
CAR T-cell therapy
6%
Chemokine
8%
Chemokine Receptor
8%
Chimeric Antigen Receptor
15%
Chimeric Antigen Receptor T-Cell
51%
Chimeric Antigen Receptor T-Cell Immunotherapy
17%
Cisplatin
17%
Cyclophosphamide
17%
Cytokine
17%
Cytokine Production
8%
Ex Vivo
17%
Flow Cytometry
8%
Gamma Chemokine
8%
Gastrointestinal Toxicity
17%
Hazard Ratio
21%
Immune Response
15%
Immunity
8%
Immunocompetent Cell
15%
Immunotherapy
19%
Interleukin 17
17%
Intestinal Mucosal Barrier
8%
Intestinal Permeability
8%
Krukenberg Tumor
9%
Low Drug Dose
7%
Lymphocyte
34%
Lymphoid Cell
8%
Malignant Neoplasm
16%
Neoplasm
68%
Oropharyngeal Cancer
34%
Oropharynx Squamous Cell Carcinoma
8%
Ovarian Cancer
34%
Ovarian Tumor
11%
Overall Survival
25%
Pelvis Cancer
8%
Programmed Death-Ligand 1
20%
Radiation Therapy
89%
RNA Sequence
8%
Secretion (Process)
7%
Solid Malignant Neoplasm
24%
T Cell
40%
Tissue Injury
8%
Toll Like Receptor 7
17%
Tumor Antigen
19%
Tumor Cell
10%
Tumor Infiltrating Lymphocyte
17%
Tumor Microenvironment
17%
Tumor Model
17%
Pharmacology, Toxicology and Pharmaceutical Science
Actin
17%
Acute Lymphoblastic Leukemia
5%
B Cell Lymphoma
26%
Carcinoembryonic Antigen
17%
CD19 Antigen
13%
CD8 Antigen
11%
Chemokine
8%
Chemokine Receptor
8%
Chemotherapy
28%
Chimeric Antigen Receptor
17%
Chronic Lymphatic Leukemia
9%
Cisplatin
9%
Combination Therapy
9%
Cyclophosphamide
17%
Cytokine
25%
Dendritic Cell Vaccine
5%
Flow Cytometry
8%
Gamma Chemokine
8%
Gastrointestinal Toxicity
17%
Hexametaphosphate Sodium
17%
Immune Checkpoint Inhibitor
8%
Immunoglobulin
14%
Immunosuppressive Agent
5%
Immunotherapy
18%
Interleukin 17
17%
Intestinal Permeability
8%
Ipilimumab
5%
Malignant Neoplasm
27%
MedImmune
17%
Melanoma
5%
Mouse
15%
Neoplasm
74%
Obinutuzumab
34%
Oropharynx Cancer
17%
Ovary Cancer
17%
Overall Survival
14%
Pelvis Cancer
8%
Programmed Cell Death
10%
Programmed Death 1 Receptor
17%
Receptor
11%
Recombinant Antibody
5%
Rituximab
27%
RNA-Sequencing
8%
Solid Malignant Neoplasm
17%
T Lymphocyte Receptor
5%
Tissue Injury
8%
Toll Like Receptor 7
17%
Tumor Microenvironment
17%
Tumor Model
17%
Virus Vaccine
5%
